Here are the Identifying predictors of sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide 1 receptor agonist use in hospital among adults with diabetes journals presenting the latest research across various disciplines. From social sciences to technology, each article is expected to provide valuable insights to our readers.
What is sodium glucose, glucose and sodium relationship, lab results for glucose, calculate sodium levels with hyperglycemia, observations of sodium in water.
Identifying predictors of sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide 1 receptor agonist use in hospital among adults with diabetes
Aims: To identify factors associated with use of novel diabetes medications among patients hospitalized under general internal medicine.
Methods: We conducted a cohort study of patients with type 2 diabetes mellitus (T2DM) hospitalized in Ontario, Canada between 2015 and 2020. We evaluated the patient- and physician-level factors associated with sodium-glucose cotransporter 2 inhibitor (SGLT2) and glucagon-like peptide 1 receptor agonist (GLP1R) use using a multivariable logistic regression model.
Results: There were 253,152 hospitalizations and 68,126 involved patients who had T2DM. Prior to discharge, 3.7 % (N = 2490) of patients with T2DM received an SGLT2 and 0.2 % (N = 121) received a GLP1R. The strongest predictors for receiving a novel diabetes medication were hemoglobin A1C > 9.0 % (Odds Ratio (OR) = 1.81, 95 % Confidence Interval (CI) 1.28, 2.60) and patients aged 40–60 compared with patients <40 years old (OR = 1.81, 95 % CI 1.33, 2.68). The strongest predictors for not receiving a novel diabetes medication were dementia (OR = 0.47, 95 % CI 0.39, 0.56) and creatinine ≥200 μmol/L (OR = 0.11, 95 % CI 0.08, 0.15). Overall, 46.8 % of patients hospitalized with T2DM not receiving a novel diabetes medication would potentially benefit from an SGLT2 inhibitor. Conclusions: Novel diabetes medications were rarely continued or initiated during hospitalization despite a high prevalence of cardiovascular disease, raising the concern for systematic under-utilization after discharge. © 2024 The Authors
Authors : Raudanskis A.; Sarma S.; Biering-Sørensen T.; Zorcic K.; Razak F.; Verma A.; Jensen M.T.; Perkins B.A.; Colacci M.; Fralick M.
Source : Elsevier Inc.
Article Information
| Year | 2025 |
| Type | Article |
| DOI | 10.1016/j.jdiacomp.2024.108945 |
| ISSN | 10568727 |
| Volume | 39 |
You can download the article here
If You have any problem, contact us here